AddLife AB (publ) (ALIF_B) Q2 2025 Earnings Call

Investor webinar replay

Watch the replay and follow the connected company analysis, news, and investor updates for Addlife Ab Class B.

Watch the replay

Replay transcript excerpt

WEBVTT 00:00:00.200 -- 00:00:05.727 Good morning, everyone, and a warm welcome to the AdLife second quarter report. 00:00:05.727 -- 00:00:09.172 Kristina and I will take you through the highlights of the report. 00:00:09.172 -- 00:00:12.597 And after that, we will have a Q&A session as always. 00:00:12.597 -- 00:00:17.503 And as you may remember, we like to show you a little bit of a summary of some of our 00:00:17.503 -- 00:00:22.670 companies. So this time around, we are we have recorded the video with MBA, 00:00:22.670 -- 00:00:27.250 our Spanish and Portuguese company that are fantastic in orthopedic surgery. 00:00:27.250 -- 00:00:32.517 and now expanding into other fields of advanced surgery and hospital products. 00:00:32.517 -- 00:00:34.779 But let's get started now with the numbers. 00:00:34.779 -- 00:00:38.885 So I'm really pleased to share with you all that the AdLife companies continue to deliver 00:00:38.885 -- 00:00:43.591 on the priorities that we have set out. And the number one priority, as you may remember, 00:00:43.591 -- 00:00:48.717 is to improve margins and profit. So we saw a significant margin improvement 00:00:48.717 -- 00:00:53.403 in both business areas, actually, both lab tech and med tech 00:00:53.403 -- 00:00:58.538 achieving a level above 12 percent EBITDA margin, and that's a significant 00:00:58.538 -- 00:01:03.623 increase for both business areas. We saw a healthy customer demand, and 00:01:03.623 -- 00:01:07.306 the currency-adjusted sales increased by 5 percent. 00:01:07.306 -- 00:01:12.171 Organic growth was 3, and really pleased to note that we see a meaningful impact of the 00:01:12.171 -- 00:01:18.296 acquisitions we have made recently, so acquisitions contributed with 2 percent. 00:01:18.296 -- 00:01:23.361 In Labtech, we had a...